Standard BioTools Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Standard BioTools (NASDAQ:LAB) Full Year 2024 Results

Key Financial Results

• Revenue: US$174.4m (up 64% from FY 2023).
• Net loss: US$138.9m (loss widened by 86% from FY 2023).
• US$0.39 loss per share.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Standard BioTools Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) missed analyst estimates by 18%.

Looking ahead, revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Life Sciences industry in the US.

Performance of the American Life Sciences industry.

The company's shares are down 23% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Standard BioTools has 3 warning signs we think you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.